Matthew A Lines1, Rebekah Jobling, Lauren Brady, Christian R Marshall, Stephen W Scherer, Amadeo R Rodriguez, Liesly Lee, Anthony E Lang, Tiago A Mestre, Ronald J A Wanders, Sacha Ferdinandusse, Mark A Tarnopolsky. 1. From Metabolics and Newborn Screening (M.A.L.), University of Ottawa, Children's Hospital of Eastern Ontario; Clinical and Metabolic Genetics (R.J.), and The Centre for Applied Genomics and Program in Genetics and Genome Biology (C.R.M., S.W.S.), The Hospital for Sick Children, Toronto; Neuromuscular and Neuorometabolic Disorders (L.B., M.A.T.), and Department of Ophthalmology (A.R.R.), McMaster University, Hamilton; Department of Molecular Genetics, McLaughlin Centre (C.R.M., S.W.S.), and Division of Neurology, Sunnybrook Health Sciences Centre (L.L.), University of Toronto; Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease (A.E.L., T.A.M.), Toronto Western Hospital, Canada; and Laboratory Genetic Metabolic Diseases (R.J.A.W., S.F.), Academic Medical Center, University of Amsterdam, the Netherlands.
Abstract
OBJECTIVE: To determine the causative genetic lesion in 3 adult siblings with a slowly progressive, juvenile-onset phenotype comprising cerebellar atrophy and ataxia, intellectual decline, hearing loss, hypogonadism, hyperreflexia, a demyelinating sensorimotor neuropathy, and (in 2 of 3 probands) supratentorial white matter changes, in whom numerous prior investigations were nondiagnostic. METHODS: The patients' initial clinical assessment included history and physical examination, cranial MRI, and nerve conduction studies. We performed whole-exome sequencing of all 3 probands, followed by variant annotation and selection of rare, shared, recessive coding changes to identify the gene responsible. We next performed a panel of peroxisomal investigations in blood and cultured fibroblasts, including assessment of D-bifunctional protein (DBP) stability and activity by immunoblot and enzymologic methods, respectively. RESULTS: Exome sequencing identified compound heterozygous mutations in HSD17B4, encoding peroxisomal DBP, in all 3 probands. Both identified mutations alter a conserved residue within the active site of DBP's enoyl-CoA hydratase domain. Routine peroxisomal screening tests, including very long-chain fatty acids and phytanic acid, were normal. DBP enzymatic activity was markedly reduced. CONCLUSION: Exome sequencing provides a powerful and elegant tool in the specific diagnosis of "mild" or "atypical" neurometabolic disorders. Given the broad differential diagnosis and the absence of detectable biochemical abnormalities in blood, molecular testing of HSD17B4 should be considered as a first-line investigation in patients with compatible features.
OBJECTIVE: To determine the causative genetic lesion in 3 adult siblings with a slowly progressive, juvenile-onset phenotype comprising cerebellar atrophy and ataxia, intellectual decline, hearing loss, hypogonadism, hyperreflexia, a demyelinating sensorimotor neuropathy, and (in 2 of 3 probands) supratentorial white matter changes, in whom numerous prior investigations were nondiagnostic. METHODS: The patients' initial clinical assessment included history and physical examination, cranial MRI, and nerve conduction studies. We performed whole-exome sequencing of all 3 probands, followed by variant annotation and selection of rare, shared, recessive coding changes to identify the gene responsible. We next performed a panel of peroxisomal investigations in blood and cultured fibroblasts, including assessment of D-bifunctional protein (DBP) stability and activity by immunoblot and enzymologic methods, respectively. RESULTS: Exome sequencing identified compound heterozygous mutations in HSD17B4, encoding peroxisomal DBP, in all 3 probands. Both identified mutations alter a conserved residue within the active site of DBP's enoyl-CoA hydratase domain. Routine peroxisomal screening tests, including very long-chain fatty acids and phytanic acid, were normal. DBP enzymatic activity was markedly reduced. CONCLUSION: Exome sequencing provides a powerful and elegant tool in the specific diagnosis of "mild" or "atypical" neurometabolic disorders. Given the broad differential diagnosis and the absence of detectable biochemical abnormalities in blood, molecular testing of HSD17B4 should be considered as a first-line investigation in patients with compatible features.
Authors: Y Suzuki; L L Jiang; M Souri; S Miyazawa; S Fukuda; Z Zhang; M Une; N Shimozawa; N Kondo; T Orii; T Hashimoto Journal: Am J Hum Genet Date: 1997-11 Impact factor: 11.025
Authors: Sarah B Pierce; Tom Walsh; Karen M Chisholm; Ming K Lee; Anne M Thornton; Agata Fiumara; John M Opitz; Ephrat Levy-Lahad; Rachel E Klevit; Mary-Claire King Journal: Am J Hum Genet Date: 2010-07-30 Impact factor: 11.025
Authors: P T Clayton; B D Lake; M Hjelm; J B Stephenson; G T Besley; R J Wanders; A W Schram; J M Tager; R B Schutgens; A M Lawson Journal: J Inherit Metab Dis Date: 1988 Impact factor: 4.982
Authors: Sacha Ferdinandusse; Simone Denis; Petra A W Mooyer; Conny Dekker; Marinus Duran; Roelineke J Soorani-Lunsing; Eugen Boltshauser; Alfons Macaya; Jutta Gärtner; Charles B L M Majoie; Peter G Barth; Ronald J A Wanders; Bwee Tien Poll-The Journal: Ann Neurol Date: 2006-01 Impact factor: 10.422
Authors: Sacha Ferdinandusse; Mari S Ylianttila; Jolein Gloerich; M Kristian Koski; Wendy Oostheim; Hans R Waterham; J Kalervo Hiltunen; Ronald J A Wanders; Tuomo Glumoff Journal: Am J Hum Genet Date: 2005-11-15 Impact factor: 11.025
Authors: J Adamski; F Leenders; J F Carstensen; M Kaufmann; M M Markus; B Husen; J G Tesdorpf; U Seedorf; Y de Launoit; F Jakob Journal: Steroids Date: 1997-01 Impact factor: 2.668
Authors: Simon Verheijden; Astrid Bottelbergs; Olga Krysko; Dmitri V Krysko; Lien Beckers; Stephanie De Munter; Paul P Van Veldhoven; Sabine Wyns; Wim Kulik; Klaus-Armin Nave; Matt S Ramer; Peter Carmeliet; Celia M Kassmann; Myriam Baes Journal: Neurobiol Dis Date: 2013-06-15 Impact factor: 5.996
Authors: J Adamski; T Normand; F Leenders; D Monté; A Begue; D Stéhelin; P W Jungblut; Y de Launoit Journal: Biochem J Date: 1995-10-15 Impact factor: 3.857
Authors: Hugh J McMillan; Thea Worthylake; Jeremy Schwartzentruber; Chloe C Gottlieb; Sarah E Lawrence; Alex Mackenzie; Chandree L Beaulieu; Petra A W Mooyer; Ronald J A Wanders; Jacek Majewski; Dennis E Bulman; Michael T Geraghty; Sacha Ferdinandusse; Kym M Boycott Journal: Orphanet J Rare Dis Date: 2012-11-22 Impact factor: 4.123
Authors: David J Amor; Ashley P L Marsh; Elsdon Storey; Rick Tankard; Greta Gillies; Martin B Delatycki; Kate Pope; Catherine Bromhead; Richard J Leventer; Melanie Bahlo; Paul J Lockhart Journal: Neurol Genet Date: 2016-10-18
Authors: Sacha Ferdinandusse; Merel S Ebberink; Frédéric M Vaz; Hans R Waterham; Ronald J A Wanders Journal: J Inherit Metab Dis Date: 2016-03-04 Impact factor: 4.982
Authors: Kevin Berendse; Marc Engelen; Sacha Ferdinandusse; Charles B L M Majoie; Hans R Waterham; Frédéric M Vaz; Johannes H T M Koelman; Peter G Barth; Ronald J A Wanders; Bwee Tien Poll-The Journal: J Inherit Metab Dis Date: 2015-08-19 Impact factor: 4.982